Travis Steed
Stock Analyst at Barclays
(2.69)
# 2,148
Out of 5,050 analysts
86
Total ratings
43.48%
Success rate
5.97%
Average return
Main Sectors:
Stocks Rated by Travis Steed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BDX Becton, Dickinson and Company | Maintains: Overweight | $279 → $261 | $177.84 | +46.76% | 9 | Apr 7, 2025 | |
| PEN Penumbra | Initiates: Buy | $320 | $266.19 | +20.21% | 1 | Mar 14, 2025 | |
| ABT Abbott Laboratories | Maintains: Buy | $133 → $150 | $126.36 | +18.71% | 5 | Mar 10, 2025 | |
| SOLV Solventum | Maintains: Neutral | $80 → $85 | $71.52 | +18.85% | 3 | Feb 26, 2025 | |
| EW Edwards Lifesciences | Upgrades: Buy | $82 → $90 | $83.39 | +7.93% | 4 | Dec 16, 2024 | |
| CBLL CeriBell | Initiates: Buy | $32 | $11.98 | +167.11% | 1 | Nov 5, 2024 | |
| BAX Baxter International | Maintains: Neutral | $42 → $45 | $18.00 | +150.00% | 5 | Mar 5, 2024 | |
| OM Outset Medical | Downgrades: Underperform | $480 → $45 | $12.06 | +273.13% | 1 | Oct 13, 2023 | |
| SYK Stryker | Upgrades: Buy | $315 | $356.03 | -11.52% | 5 | Sep 5, 2023 | |
| PODD Insulet | Maintains: Buy | $365 → $295 | $319.82 | -7.76% | 3 | Aug 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $16 | $23.57 | -32.12% | 5 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $33 | $16.26 | +102.95% | 2 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 → $160 | $88.50 | +80.79% | 11 | May 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $315 | $560.00 | -43.75% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $8 | $1.92 | +316.67% | 1 | Jan 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | $25 | $13.79 | +81.29% | 1 | Jun 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $85 | $14.45 | +488.24% | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $125 | $55.00 | +127.27% | 7 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Equal-Weight | $145 | $92.20 | +57.27% | 1 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $51 | $100.02 | -49.01% | 9 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $175 | $43.97 | +298.00% | 4 | May 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $59 → $54 | $12.04 | +348.50% | 2 | Nov 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $51.07 | -56.92% | 1 | Jul 17, 2017 |
Becton, Dickinson and Company
Apr 7, 2025
Maintains: Overweight
Price Target: $279 → $261
Current: $177.84
Upside: +46.76%
Penumbra
Mar 14, 2025
Initiates: Buy
Price Target: $320
Current: $266.19
Upside: +20.21%
Abbott Laboratories
Mar 10, 2025
Maintains: Buy
Price Target: $133 → $150
Current: $126.36
Upside: +18.71%
Solventum
Feb 26, 2025
Maintains: Neutral
Price Target: $80 → $85
Current: $71.52
Upside: +18.85%
Edwards Lifesciences
Dec 16, 2024
Upgrades: Buy
Price Target: $82 → $90
Current: $83.39
Upside: +7.93%
CeriBell
Nov 5, 2024
Initiates: Buy
Price Target: $32
Current: $11.98
Upside: +167.11%
Baxter International
Mar 5, 2024
Maintains: Neutral
Price Target: $42 → $45
Current: $18.00
Upside: +150.00%
Outset Medical
Oct 13, 2023
Downgrades: Underperform
Price Target: $480 → $45
Current: $12.06
Upside: +273.13%
Stryker
Sep 5, 2023
Upgrades: Buy
Price Target: $315
Current: $356.03
Upside: -11.52%
Insulet
Aug 24, 2023
Maintains: Buy
Price Target: $365 → $295
Current: $319.82
Upside: -7.76%
Aug 22, 2023
Reiterates: Overweight
Price Target: $16
Current: $23.57
Upside: -32.12%
May 5, 2023
Downgrades: Underperform
Price Target: $45 → $33
Current: $16.26
Upside: +102.95%
May 3, 2023
Upgrades: Neutral
Price Target: $120 → $160
Current: $88.50
Upside: +80.79%
Apr 19, 2023
Maintains: Buy
Price Target: $300 → $315
Current: $560.00
Upside: -43.75%
Jan 3, 2023
Downgrades: Underperform
Price Target: $8
Current: $1.92
Upside: +316.67%
Jun 21, 2022
Initiates: Underperform
Price Target: $25
Current: $13.79
Upside: +81.29%
Oct 13, 2021
Maintains: Overweight
Price Target: $120 → $85
Current: $14.45
Upside: +488.24%
May 25, 2021
Initiates: Overweight
Price Target: $125
Current: $55.00
Upside: +127.27%
May 25, 2021
Initiates: Equal-Weight
Price Target: $145
Current: $92.20
Upside: +57.27%
May 25, 2021
Initiates: Overweight
Price Target: $51
Current: $100.02
Upside: -49.01%
May 25, 2021
Initiates: Overweight
Price Target: $175
Current: $43.97
Upside: +298.00%
Nov 1, 2018
Maintains: Neutral
Price Target: $59 → $54
Current: $12.04
Upside: +348.50%
Jul 17, 2017
Initiates: Overweight
Price Target: $22
Current: $51.07
Upside: -56.92%